John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.
A 67-Year-Old Man with Chronic Lymphocytic Leukemia
A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.
John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.
A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.
John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.
An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.
John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
5